What is B. Riley’s Forecast for Cytokinetics Q2 Earnings?

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities researchers at B. Riley raised their Q2 2025 EPS estimates for shares of Cytokinetics in a research report issued to clients and investors on Wednesday, May 7th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post earnings of ($1.37) per share for the quarter, up from their previous estimate of ($1.40). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.46) EPS, Q4 2025 earnings at ($1.42) EPS, FY2025 earnings at ($5.61) EPS, FY2026 earnings at ($5.55) EPS, FY2027 earnings at ($4.70) EPS, FY2028 earnings at ($2.53) EPS and FY2029 earnings at $0.74 EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.05. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.77 million. The business’s quarterly revenue was up 89.1% on a year-over-year basis. During the same period last year, the firm earned ($1.33) EPS.

CYTK has been the topic of a number of other research reports. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a research report on Thursday, April 10th. Stifel Nicolaus began coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price target on the stock. UBS Group reduced their price objective on shares of Cytokinetics from $47.00 to $41.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada lowered their target price on shares of Cytokinetics from $82.00 to $80.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Bank of America reduced their price target on Cytokinetics from $62.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 15th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.44.

Cytokinetics Trading Down 2.4 %

Shares of NASDAQ:CYTK opened at $31.69 on Friday. The company has a market capitalization of $3.78 billion, a PE ratio of -5.89 and a beta of 0.81. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics has a 12-month low of $31.67 and a 12-month high of $64.61. The business’s fifty day simple moving average is $40.18 and its 200-day simple moving average is $46.01.

Insider Activity

In related news, CEO Robert I. Blum sold 16,970 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.44, for a total value of $737,176.80. Following the sale, the chief executive officer now owns 364,181 shares in the company, valued at $15,820,022.64. This represents a 4.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wendall Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $38.46, for a total transaction of $769,200.00. Following the transaction, the director now directly owns 24,848 shares of the company’s stock, valued at $955,654.08. This represents a 44.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,362 shares of company stock valued at $3,899,118. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its stake in shares of Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Cytokinetics in the fourth quarter worth about $29,000. Fifth Third Bancorp grew its holdings in Cytokinetics by 42.2% during the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 291 shares during the period. Parallel Advisors LLC raised its position in Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 916 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Cytokinetics by 281.0% in the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 826 shares during the period.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.